- Home
- ARVN vs MCS Comparison
ARVN vs MCS Comparison
Compare ARVN & MCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- MCS
- Stock Information
- Founded
- ARVN 2015
- MCS 1935
- Country
- ARVN United States
- MCS United States
- Employees
- ARVN N/A
- MCS N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- MCS Movies/Entertainment
- Sector
- ARVN Health Care
- MCS Consumer Discretionary
- Exchange
- ARVN Nasdaq
- MCS Nasdaq
- Market Cap
- ARVN 456.2M
- MCS 537.6M
- IPO Year
- ARVN 2018
- MCS N/A
- Fundamental
- Price
- ARVN $7.73
- MCS $16.98
- Analyst Decision
- ARVN Buy
- MCS Strong Buy
- Analyst Count
- ARVN 21
- MCS 4
- Target Price
- ARVN $20.53
- MCS $23.75
- AVG Volume (30 Days)
- ARVN 2.1M
- MCS 160.4K
- Earning Date
- ARVN 07-29-2025
- MCS 07-31-2025
- Dividend Yield
- ARVN N/A
- MCS 1.65%
- EPS Growth
- ARVN N/A
- MCS N/A
- EPS
- ARVN N/A
- MCS N/A
- Revenue
- ARVN $426,900,000.00
- MCS $704,626,000.00
- Revenue This Year
- ARVN $4.26
- MCS $13.05
- Revenue Next Year
- ARVN N/A
- MCS $4.23
- P/E Ratio
- ARVN N/A
- MCS N/A
- Revenue Growth
- ARVN 498.74
- MCS 3.81
- 52 Week Low
- ARVN $5.90
- MCS $10.45
- 52 Week High
- ARVN $34.11
- MCS $23.16
- Technical
- Relative Strength Index (RSI)
- ARVN 50.16
- MCS 43.29
- Support Level
- ARVN $7.09
- MCS $16.49
- Resistance Level
- ARVN $7.89
- MCS $17.14
- Average True Range (ATR)
- ARVN 0.35
- MCS 0.37
- MACD
- ARVN 0.00
- MCS -0.08
- Stochastic Oscillator
- ARVN 38.14
- MCS 24.80
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.